Paper Details

  1. Home
  2. Paper Details

AR101 Oral Immunotherapy for Peanut Allergy.

Author: , AdelmanDaniel C, AnagnostouAikaterini, Assa’adAmal H, Ben-ShoshanMoshe, BeyerKirsten, Bindslev-JensenCarsten, BirdJ Andrew, BlumchenKatharina, BurksA Wesley, CarrTara F, CarrWarner W, CasaleThomas B, CheemaAmarjit, ChinthrajahSharon, ChongHey J, CiaccioChristina E, DillyStephen G, DorseyMorna J, DuboisAnthony E J, Fernández-RivasMontserrat, FinemanStanley, FleischerDavid M, FritzStephen B, GreosLeon, HampelFrank C, HourihaneJonathan O, IbáñezM Dolores, JeongDavid K, JohnstonDouglas T, JonesStacie M, KachruRita, KimEdwin H, LanserBruce J, LeicklyFrederick E, LeonardStephanie, LiebermanJay A, MansfieldLyndon E, MarcantonioAnnette, MatzJonathan, MuraroAntonella, NilssonCaroline, OhayonJason, Oude ElberinkHanneke N G, PongracicJacqueline A, PortnoyJay M, RachidRima, RuppNed, SandersGeorgiana M, SharmaHemant P, SharmaVibha, SherEllen, SherLawrence, ShrefflerWayne G, SiriDareen, SpergelJonathan M, StillermanAllan, SussmanGordon, TillesStephen, TsoumaniMarina, VarshneyPooja, VeredaAndrea, VickeryBrian P, WangJulie, WelchMichael J, WindomHugh H, WoodRobert A, YangWilliam H, ZawadzkiRezi, ZielenStefan, ZubeldiaJosé M, du ToitGeorge

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Treatment with AR101, a peanut-derived investigational biologic oral immunotherapy drug, resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure than placebo in children and adolescents with peanut allergy. Efficacy was not demonstrated in adults.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Peanut allergy, for which there are no approved treatment options, affects patients who are at risk for unpredictable and occasionally life-threatening allergic reactions. METHODS: In a phase 3 trial, we screened participants 4 to 55 years of age with peanut allergy for allergic dose-li...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1812856

データ提供：米国国立医学図書館（NLM）

Peanut Allergy: A Promising New Treatment

Peanut allergy, a tricky beast in the field of medicine, has long been a source of worry for those who experience life-threatening reactions to this delicious legume. This study delves into the world of oral immunotherapy, using a peanut-derived drug called AR101 to tackle this allergic challenge. The researchers employed a clever double-blind, placebo-controlled study, like a treasure hunt in the desert, where participants were randomly assigned to receive either the magical AR101 or a plain placebo. The goal was to see if AR101 could help individuals with peanut allergy ingest larger amounts of peanut protein without experiencing those dreadful allergic reactions. The findings were quite promising, with a significant increase in the number of participants in the AR101 group able to tolerate a higher dose of peanut protein compared to those who received the placebo. This suggests that AR101 could be a real game-changer for people with peanut allergies, paving the way for a more relaxed relationship with this nutty delicacy.

A Beacon of Hope for Peanut Allergy Sufferers

The results of this study are truly exciting, offering a glimmer of hope to those who struggle with peanut allergies. The fact that a large percentage of participants in the AR101 group were able to tolerate a much higher dose of peanut protein without experiencing severe reactions is a remarkable accomplishment. This discovery could potentially revolutionize the way we manage peanut allergies, transforming the lives of those who have been living in constant fear of a potentially life-threatening reaction.

Embracing Peanuts With a Little Caution

While the results are promising, it's important to remember that this study involved children and adolescents, and the effects on adults are still under investigation. It's crucial to consult with a healthcare professional for personalized advice and to follow all recommended safety precautions. This study may represent a significant step forward in the treatment of peanut allergy, but it's not a magic bullet. It's essential to continue researching and exploring all possible avenues to combat this complex medical challenge.

Dr.Camel's Conclusion

This study is a ray of hope for peanut allergy sufferers, like a refreshing oasis in the vast desert of allergic reactions. It demonstrates the potential of AR101 to significantly improve the lives of those who struggle with peanut allergy. However, it's important to approach this new treatment with a healthy dose of optimism and caution, as further research is still needed to fully understand its long-term effects. The desert of peanut allergy research is still vast, and we must continue to explore new paths, like a camel caravan seeking a new route, to find a truly effective solution for this common allergy.
Date :
  1. Date Completed 2018-12-11
  2. Date Revised 2019-02-20
Further Info :

Pubmed ID

30449234

DOI: Digital Object Identifier

10.1056/NEJMoa1812856

Related Literature

Article Analysis
・Effective treatment of allergy
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.